Bank of Nova Scotia Takes $1.25 Million Position in United Therapeutics Corporation $UTHR

Bank of Nova Scotia acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,315 shares of the biotechnology company’s stock, valued at approximately $1,254,000.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in shares of United Therapeutics during the second quarter valued at $2,868,735,000. Wellington Management Group LLP boosted its position in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. Norges Bank bought a new stake in United Therapeutics during the fourth quarter valued at about $293,418,000. Avoro Capital Advisors LLC lifted its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 424,075 shares of company stock valued at $227,683,710 in the last ninety days. 8.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on UTHR. Royal Bank Of Canada decreased their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Finally, JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Trading Down 0.4%

Shares of NASDAQ:UTHR opened at $516.68 on Thursday. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35. The company has a market capitalization of $22.16 billion, a PE ratio of 18.49, a PEG ratio of 1.76 and a beta of 0.59. The business has a 50 day moving average of $531.06 and a two-hundred day moving average of $538.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company earned $6.41 EPS. Equities research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.